<DOC>
	<DOCNO>NCT01829750</DOCNO>
	<brief_summary>The purpose study investigate efficacy intracoronary infusion cardiac progenitor cell patient univentricular heart disease . Patients preoperative high-risk group whose cardiac function recover postoperatively eventually choice heart transplantation .</brief_summary>
	<brief_title>Cardiac Progenitor Cell Infusion Treat Univentricular Heart Disease ( PERSEUS )</brief_title>
	<detailed_description>Following safety verification Phase I study ( TICAP trial ) implement complete , efficacy verify Phase II clinical study . The rationale study base animal study transplant cardiac progenitor cell may regenerate damaged myocardium give rise cardiac muscle vascular cell type . Preclinical phase I study indicate possibility cardiac function improvement reduce myocardial fibrosis progenitor cell infusion . The efficacy cell transplantation assess primary endpoint Phase II clinical study . The improvement cardiac ejection fraction assess echocardiography , ventriculography , cardiac MRI , conduct treatment , assess evaluation item . The absolute value improvement cardiac ejection fraction obtain three image modality treatment compare two group transplantation group non-transplantation group .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
	<criteria>1 . Age : Age 0 year 20 year less time enrollment . 2 . The patient functional single ventricular physiology indication stage2 3 palliative surgery . 3 . The ventricular ejection fraction &lt; 60 % . 1 . Cardiogenic shock 2 . A patient unstoppable extracorporeal circulation 3 . A patient lethal , uncontrollable arrhythmia 4 . A patient complication coronary artery disease 5 . A patient complication brain dysfunction due circulatory failure 6 . A patient malignant neoplasm 7 . A patient complication serious neurologic disorder 8 . A patient highgrade pulmonary embolism pulmonary hypertension 9 . A patient highgrade renal failure 10 . A patient multiple organ failure 11 . Active infection ( include endocarditis ) 12 . Sepsis 13 . Active hemorrhagic disease ( e. g. gastrointestinal bleeding , injury )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Univentricular heart</keyword>
</DOC>